NLR Cancer Research Results

NLR, neutrophil-to-lymphocyte ratio (NLR): Click to Expand ⟱
Source:
Type: BioMarker

Neutrophil-to-lymphocyte ratio (NLR) is a calculated blood-based inflammatory biomarker obtained by dividing the absolute neutrophil count by the absolute lymphocyte count. It reflects the balance between systemic inflammation, represented partly by neutrophils, and lymphocyte-mediated immune activity.

In cancer, an elevated NLR is frequently associated with greater inflammatory burden, impaired antitumour immunity, more advanced disease, poorer treatment response, and reduced progression-free or overall survival. A decreased NLR is therefore generally considered the favourable direction, although its meaning depends on cancer type, disease stage, treatment, and the timing of measurement.

NLR is a nonspecific biomarker and may be altered by infection, corticosteroids, chemotherapy, granulocyte colony-stimulating factors, bone-marrow suppression, smoking, stress, and other inflammatory or medical conditions. There is no single universal cutoff value; thresholds commonly vary between approximately 3 and 5 across studies.

Calculation: absolute neutrophil count divided by absolute lymphocyte count.

Generally favourable cancer direction: decreased NLR. NLR should be classified as a hematologic biomarker or inflammatory index rather than as a direct molecular target.



Scientific Papers found: Click to Expand⟱
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, In the placebo group the proportion of T cells (CD3 +), and functionally active monocytes (CD14 + HLA-DR +) was reduced at the last cycle of chemotherapy (15 weeks) but remained constant in the DHA group
*NLR↓, The neutrophil-to-lymphocyte ratio (NLR) was maintained in the DHA group but increased in the placebo at the end of chemotherapy
eff↑, An increase in this ratio was associated with lower chance of achieving pathological complete response
*IL4↑, After 15 weeks of therapy, the DHA-supplemented group had higher concentrations of stimulated cytokines IL-4, IL-10, and the T helper type 1 cytokine IFN-γ after phytohemagglutinin (PHA) challenge, and higher concentrations of TNF-α and IFN-γ cytokin
*IL10↑,
*IFN-γ↑,
*TNF-α↑,
Imm↑, Supplementing DHA during breast cancer neoadjuvant chemotherapy improved systemic immune function by attenuating changes in blood cell concentrations, preventing depletion of immune cells
eff↑, Newell et al. [19] previously demonstrated an improvement in chemotherapy success, measured as reduced tumor weight and Ki67 activity (proliferation) in animals fed DHA (3.9% w/w of total fat) in combination with chemotherapy (docetaxel) i
TumW↓,

7481- H2,  Rad,    Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy
- Trial, Var, NA
Dose↝, The experimental group received inhalation therapy with a hydrogen-oxygen gas mixture (66.6% hydrogen, 33.3% oxygen; 3 L/min, 2 h/d) on each radiation therapy day.
CRP↓, experimental group showed significantly lower levels of C-reactive protein, neutrophil-to-lymphocyte ratio, interleukin 6, and fecal occult blood positivity rates
NLR↓,
IL6↓,
AntiTum∅, Importantly, no significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors
*toxicity↓, Hydrogen inhalation is a safe and effective adjunctive therapy that significantly alleviates inflammation and mitigates clinical symptoms of ARE in patients with cervical cancer who are undergoing CCRT, without compromising antitumor treatment outcom
Inflam↓,
radioP↑,
*IBI↑, significant reduction in fecal occult blood positivity in the hydrogen group (χ² = 16.278, P < .001), reinforcing its protective effect on intestinal mucosa integrity.
*ROS↓, Molecular hydrogen has demonstrated a unique capacity to selectively scavenge cytotoxic ROS

7932- H2,    Hydrogen Gas Inhalation Alleviates Airway Inflammation and Oxidative Stress on Ovalbumin-Induced Asthmatic BALB/c Mouse Model
- in-vivo, Asthma, NA
*antiOx↑, Molecular hydrogen (H2) has recently been recognized for its antioxidant and anti-inflammatory properties
*Inflam↓,
*ROS↓, inhaled H2 significantly reduced inflammatory cell infiltration, OS markers, and pro-inflammatory cytokine expression while upregulating antioxidant enzyme activity.
*TAC↑,
*IgE↓, Furthermore, H2 also significantly decreased serum IgE levels, a marker of allergic inflammation.
*Dose↝, 3% H2 gas inhalation on OVA-induced inflammatory airway conditions, body and lung weights were recorded in mice.
*NLR↓, Our results also demonstrated a significant decline in the NLR in the HT group compared to the NT group
*IL4↓, Conversely, the levels of IL-4 (p < 0.001; Figure 4A), IL-5 (p < 0.001; Figure 4B), IL-13 (p < 0.01; Figure 4C), and GM-CSF (p < 0.01; Figure 4F) were significantly lower in the HT group than in the NC group
*IL5↓,
*IL13↓,
*GM-CSF↓,
*NO↓, NO (p < 0.05; Figure 5B) levels were reduced in the HT group compared with those in the NC group
*GPx↑, treatment with 3% H2 significantly increased the GPx activity in the HT group compared to that in the NC group
*Eos↓, In our study, we observed that H2 inhalation reduced neutrophils in the OVA-induced asthmatic BALB/c mouse model


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NLR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum∅, 1,   radioP↑, 1,   TumW↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

Eos↓, 1,   IgE↓, 1,   IL13↓, 1,   NLR↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GPx↑, 1,   ROS↓, 2,   TAC↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   GM-CSF↓, 1,   IFN-γ↑, 1,   IL10↑, 1,   IL4↓, 1,   IL4↑, 1,   IL5↓, 1,   Inflam↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 21

Scientific Paper Hit Count for: NLR, neutrophil-to-lymphocyte ratio (NLR)
2 Hydrogen Gas
1 Docosahexaenoic Acid
1 Chemotherapy
1 Radiotherapy/Radiation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1527  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page